Scott Thomas Jackson
CIK: 0001566617
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Jun 23, 2026SPRO
Spero Therapeutics, Inc.
Award(A)Direct10K shares- - May 19, 2026MGNX
MACROGENICS INC
Award(A)DirectRestricted Stock Unit
3.8K shares- - May 19, 2026MGNX
MACROGENICS INC
Award(A)DirectStock Option (right to buy)
22K shares- - May 18, 2026MGNX
MACROGENICS INC
Exercise(M)Direct3.8K shares- - Dec 5, 2025MURA
Mural Oncology plc
Disposition(D)DirectStock Option (right to buy)
8.6K shares- - Dec 5, 2025MURA
Mural Oncology plc
Disposition(D)DirectStock Option (right to buy)
8.5K shares- - Dec 5, 2025MURA
Mural Oncology plc
Disposition(D)DirectStock Option (right to buy)
15K shares- - Jun 12, 2025SPRO
Spero Therapeutics, Inc.
Award(A)Direct20K shares- - Jun 11, 2025MURA
Mural Oncology plc
Award(A)DirectStock Option (right to buy)
8.6K shares- - May 21, 2025MGNX
MACROGENICS INC
Award(A)DirectStock Option (right to buy)
22K shares- - May 21, 2025MGNX
MACROGENICS INC
Award(A)DirectRestricted Stock Unit
3.8K shares- - May 20, 2025MGNX
MACROGENICS INC
Exercise(M)Direct6.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 23, 2026 |  SPRO Spero Therapeutics, Inc. | Award(A) | 10,000 | - | $0 | Direct |
| May 19, 2026 |  MGNX MACROGENICS INC | Award(A) Restricted Stock Unit | 3,750 | - | - | Direct |
| May 19, 2026 | MGNX MACROGENICS INC | Award(A) Stock Option (right to buy) | 22,000 | - | - | Direct |
| May 18, 2026 | MGNX MACROGENICS INC | Exercise(M) | 3,750 | - | $0 | Direct |
| Dec 5, 2025 |  MURA Mural Oncology plc | Disposition(D) Stock Option (right to buy) | 8,637 | - | - | Direct |
| Dec 5, 2025 | MURA Mural Oncology plc | Disposition(D) Stock Option (right to buy) | 8,462 | - | - | Direct |
| Dec 5, 2025 | MURA Mural Oncology plc | Disposition(D) Stock Option (right to buy) | 15,021 | - | - | Direct |
| Jun 12, 2025 | SPRO Spero Therapeutics, Inc. | Award(A) | 20,000 | - | - | Direct |
| Jun 11, 2025 | MURA Mural Oncology plc | Award(A) Stock Option (right to buy) | 8,637 | - | - | Direct |
| May 21, 2025 | MGNX MACROGENICS INC | Award(A) Stock Option (right to buy) | 22,000 | - | - | Direct |
| May 21, 2025 | MGNX MACROGENICS INC | Award(A) Restricted Stock Unit | 3,750 | - | - | Direct |
| May 20, 2025 | MGNX MACROGENICS INC | Exercise(M) | 6,500 | - | - | Direct |
1-12 of 12 transactions
About Jackson Scott Thomas
Jackson Scott Thomas (SEC CIK 0001566617) files insider reports with the SEC as Director of Spero Therapeutics, Inc. (SPRO), Director of MACROGENICS INC (MGNX) and Director of Mural Oncology plc (MURA).
Signal8 holds 6 ownership filings by Jackson Scott Thomas, all Form 4s, filed between May 22, 2025 and Jun 25, 2026. Those filings report 12 transactions, from May 20, 2025 to Jun 23, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Jackson Scott Thomas's filings is in CAMBRIDGE, MA.
Recent filings by Jackson Scott Thomas
- Jun 23, 2026: Grant or award of SPRO shares (Form 4, code A).
- May 19, 2026: Grants or awards of MGNX derivative securities (2 lines, Form 4, code A).
- May 18, 2026: Option exercise of MGNX shares (Form 4, code M).
- Dec 5, 2025: Disposition to issuer transactions of MURA derivative securities (3 lines, Form 4, code D).
- Jun 12, 2025: Grant or award of SPRO shares (Form 4, code A).
Other insiders filing for Spero Therapeutics, Inc. (SPRO)
- Zack Debra, Chief Medical Officer
- Deshpande Milind, Director
- Tregoning Kathleen, Director
- Smith Cynthia, Director
- VINK PATRICK V.J.J., Director
- THOMAS FRANK E, Director